Skip to main navigation
Phio Pharmaceuticals

Phio Pharmaceuticals

  • Home
  • Company
    • Leadership
    • Career Opportunities
    • About
  • Focus
    • Cancer Immunotherapy
    • Our Approach
    • Pipeline
    • Collaboration
  • Technology
    • RNAi mechanism
    • Self-delivering RNAi
  • Investors
    • News Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors & Scientific Board
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Institutional Ownership
      • Annual Reports
      • Form 8937
    • Email Alerts
    • Contact Us

  • Home
  • Company
    • Leadership
    • Career Opportunities
    • About
  • Focus
    • Cancer Immunotherapy
    • Our Approach
    • Pipeline
    • Collaboration
  • Technology
    • RNAi mechanism
    • Self-delivering RNAi
  • Investors
    • News Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors & Scientific Board
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Institutional Ownership
      • Annual Reports
      • Form 8937
    • Email Alerts
    • Contact Us

Investor Relations

SEC Filings

SEC Filing Details

Document Details

Form
4
Filing Date
Mar 5, 2021
Document Date
Mar 4, 2021
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Phio Pharmaceuticals
Issuer
Phio Pharmaceuticals Corp.
Filer
Dispersyn Gerrit

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Print Page
  • Email Page
  • RSS Feeds
  • Email Alerts
  • IR Contact
  • Share
2021 Terms | Privacy Policy
TOP